Techonology and Science24 September, 20252 min read
UK Scientists Slow Huntington’s Disease Progression by 75% with Gene Therapy in Groundbreaking Trial
AMT-130 gene therapy slowed Huntington’s disease progression by 75% over three years. The treatment involves a one-time neurosurgical procedure delivering a modified viral vector.
39 outlets told this the same way.
Breakthrough in Huntington's Treatment
UK scientists have achieved a significant breakthrough in the treatment of Huntington's disease, a fatal genetic disorder, by using a novel gene therapy called AMT-130. This therapy, developed by the Dutch biotech company uniQure, involves delivering microRNA via a harmless virus to brain cells, which reduces the production of the harmful huntingtin protein responsible for the disease.
“A groundbreaking new gene therapy trial has shown the ability to slow the progression of Huntington's disease by up to 75%, potentially extending patients' quality of life from one year of decline to four years.”
In a clinical trial involving 29 patients, those receiving a high dose of the therapy experienced a 75% reduction in disease progression over three years. This marks a major advancement in treating Huntington's disease, which currently has no cure and affects thousands worldwide.
Brain Therapy Trial Results
The trial, led by Professors Sarah Tabrizi and Ed Wild at University College London, involved a complex surgical procedure to deliver the therapy directly into the brain. The treatment showed a dose-dependent effect, with higher doses yielding better results.
Patients receiving the high dose not only showed a significant reduction in disease progression but also improved motor function, cognition, and quality of life. The therapy was generally well-tolerated, with side effects mainly related to the surgical procedure itself, such as inflammation and headaches.
AMT-130 Huntington's Treatment
The potential impact of AMT-130 extends beyond the immediate results of the trial. Experts, including Professor Sarah Tabrizi, have described the findings as "world-changing" and anticipate that AMT-130 could become the first licensed treatment to slow Huntington's disease.
“Professor Ed Wild from UCL described the findings as potentially ‘world-changing’ and emphasized the need to make the treatment widely accessible while continuing to develop more therapies.”
However, challenges remain, including the high cost of the therapy and the complexity of the surgical procedure required for its administration. The therapy's success has renewed hope for the development of other gene-targeted treatments for neurodegenerative diseases.
Gene-Targeted Therapy Progress
The trial's success has been met with cautious optimism from the scientific community. While the results are promising, experts caution that the data has yet to undergo independent scientific review, and larger trials are necessary to confirm the findings.
The therapy's development is part of a broader trend towards gene-targeted treatments, which aim to address the underlying causes of diseases rather than just managing symptoms. This approach could revolutionize the treatment of Huntington's disease and other similar conditions.
